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Abstract 
 
New approaches that are more efficient and able to specifically reach lung tumors are needed. We 
developed new hyaluronan-based nanoparticles targeting CD44 receptors of two different sizes, 30 
and 300 nm, and compared their lung cancer cells targeting efficacy in vitro and in vivo. The 
nanoparticles cellular uptake was dose-dependent, and specific to hyaluronan receptors, particularly 
CD44. The binding and internalization differed according to nanoparticle size. In vivo 
biodistribution studies in two orthotopic lung tumor models showed that intrapulmonary nebulized 
nanoparticles accumulated in lungs, but not in the tumor nodules. In contrast, despite a significant 
liver capture, intravenous injection led to a better accumulation of the nanoparticles in the lung 
tumors compared with the surrounding healthy lung tissues. We demonstrated that the hyaluronan-
based nanoparticles size plays significant role in cellular uptake and biodistribution. Small 
nanoparticles showed active targeting of CD44-overexpressing tumors, suggesting that they could 
be used as drug-delivery system. 
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Introduction 
 
Lung cancer is the leading cause of cancer-related adult deaths worldwide (1). Non -small cell lung 
cancers (NSCLCs) account for ~85% of lung cancers (2). Despite continuous improvements in 
cancer treatments, the prognosis is poor, and the development of new approaches is urgently 
needed. In particular, major efforts have been made to generate macromolecular transporters that 
will deliver the therapeutic molecules specifically to the tumor site, protect them from immediate 
degradation, allow better control of their spatio-temporal release and thus limit their side effects (3).  
Polymeric micellar nanostructures have been demonstrated to be powerful tools to address issues of 
efficacy, specificity, and controlled release of drugs to diseased tissues (4). These structures are able 
to overcome the body's natural defenses, remain stable for an extended time in circulation, and have 
tunable physico-chemical properties, allowing control of their permeability and the kinetics of drug 
release. An active targeting of tumors can be achieved by conjugating a targeting motif that allows 
the recognition of antigens or overexpressed receptors in targeted tissues (5). 
The size of nanoparticles (NPs) is a key factor that affects their in vivo distributions (6, 7). Small 
NPs (<10 nm) are quickly cleared by the kidneys and thus have short blood half-lives. Larger NPs 
are mostly captured by the reticuloendothelial system (RES) (7). In both cases, their half-life 
depends on their stealthiness. The size of the NPs also affects their ability to flow through poorly 
structured tumor capillaries, and their endocytosis in mammalian cells (7, 8).  
The intravenous route is generally used for the administration of NPs in vivo. However, the 
inhalation of anti-tumor agents may be a local and non-invasive alternative administration route to 
improve lung cancer treatment because of the large surface area of the lungs for drug absorption and 
their extensive vasculature with a weak anatomical barrier that does not limit access to the body (9, 
10). Direct administration via the airways can increase the amount of locally delivered NPs in lung 
tumor models (9-11). 
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In the present study, we developed glycopolypeptide-based nanocarriers and evaluated their 
efficacy to target lung tumor cells in vitro and in vivo. These amphiphilic copolymers were 
combinations of the natural polysaccharide hyaluronan (Hya), known for its relative affinity toward 
CD44 receptors that are up-regulated on some cancer cells and are involved in tumor growth, 
progression and metastasis (12), and poly(J-benzyl-L-glutamate) (PBLG), a biodegradable 
polypeptide characterized by an ordered secondary structure (α-helix) (13, 14). By varying the 
hydrophilic/hydrophobic volume ratio of the copolymer and the conditions of particle formation, it 
was possible to obtain different sizes of NPs, whose we have previously shown the high drug 
loading capacity (15). Here, we evaluated the behavior of NPs of 30 nm (Np30) and 300 nm 
(Np300) in vitro in lung cancer cells with different levels of CD44. Then, we compared their in vivo 
biodistribution and tumor targeting capacity after intrapulmonary nebulization or conventional 
intravenous administration using two orthotopic lung cancer models. 
 
Methods 
 
Nanoparticle synthesis and characterization 
Synthesis of hyaluronan-b-poly(γ-benzyl-L-glutamate) copolymer by 1,3 Huisgen cycloaddition 
The strategy used was based on the coupling reaction between poly(γ-benzyl-L-glutamate) (PBLG) 
and hyaluronan (Lifecore Biomedical, MW = 5000 g/mol) using a Huisgen 1,3-dipolar 
cycloaddition click chemistry reaction, as previously described (16, 17). The reaction medium was 
dialyzed 4–5 days against MilliQ water (Spectra/Por®6 MWCO 50 kDa membrane), containing 
EDTA for the first 2 days, and then lyophilized. Next, the reaction mixture was purified by 
ultrafiltration to remove all of the unreacted hyaluronan (yield = 60%). The resulted copolymer was 
analyzed by H1NMR, FTIR and SEC in DMSO to verify the coupling conversion. 
Fluorescently labeled nanoparticles 
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Hya-b-PBLG was labeled by modifying the free amine group at the PBLG end block with the near 
infrared dye Dy-700 (Life Technologies). Briefly, the diblock copolymer (1 eq.) was dissolved in 
anhydrous DMSO (50 mg/mL), and triethylamine (1 eq. per acid function) was added. After 5 min 
of stirring, the 0.1 equivalent of Dy-700 was added, and the mixture was stirred overnight at room 
temperature. The resulting product (Hya-b-PBLG-Dy-700) was dialyzed against ultrapure water for 
one day and freeze-dried. A labeling efficiency of 10 mol% was measured in DMSO by UV 
spectroscopy (720 nm) using ε = 90,000 M-1.cm-1 according to the manufacturer’s instructions. 
Nanoparticle formulation 
NPs were formulated by a solvent displacement technique, as previously described (15). To obtain 
labeled fluorescent NPs, a mixture of Hya-b-PBLG-Dy700 and Hya-b-PBLG copolymer was 
prepared to obtain 5 mol% of labeled copolymer. To obtain different sizes, the originality was to 
use two types of copolymer with PBLG blocks varying in degree of polymerization (DP 20 and 60) 
and two different protocols for the nanoprecipitation: 
x Slow process: a solution of Hya-b-PBLG20 containing 30% w/w of homo-PBLG20 was 
prepared in DMSO (10 mg/mL) at 50°C. Using a syringe pump, phosphate buffer (10 mM, 
pH 7.4) was added at a flow rate of 70 mL/h to reach a final concentration of 1 mg/mL. 
x Fast process: Hya-b-PBLG60 was dissolved in DMSO (10 mg.mL-1) and rapidly mixed with 
a tenfold volume of phosphate buffer at 50°C using a micropipette.  
The organic solvent was then removed by dialysis (MWCO 25 kDa) against water for 24h, with the 
medium changed every 4h. The NPs were then characterized by dynamic light scattering (DLS), 
transmission electron microscopy (TEM), atomic force microscopy (AFM) and small-angle neutron 
scattering (SANS). 
 
Cell lines 
The human H322, H358 and A549 NSCLC cell lines were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA). H358 (H358-Luc) and A549 (A549-Luc) cells stably 
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expressing firefly luciferase were obtained from Optimal (Grenoble, France). 
 
Flow cytometry 
CD44 expression levels were determined after cell incubation with FITC-conjugated mouse anti-
CD44 or control IgG2bκ antibodies (BD Pharmingen, San Diego, CA) for 30 min at 4°C. NPs were 
incubated with cells for 30 min at 37°C. For competition assays, cells were previously incubated 
with 5 or 10 mg/mL sodium hyaluronan 176–350 kDa (Lifecore Biomedical) for 1h at 37°C before 
incubation with 8 µg/mL NP for 30 min at 37°C. The fluorescence intensity was analyzed using 
flow cytometry LSRII and FCS Express software (BD Biosciences, San Jose, US). 
 
Immunofluorescence and microscopy 
Cells were seeded on glass coverslips coated with 1 µg/mL fibronectin and 1% bovine serum 
albumin. After washing, NPs were incubated for 30 min at 4°C or 37°C. The cells were then 
washed and fixed in 0.1% saponin and 2% paraformaldehyde for 15 min. Nuclei were labeled with 
DAPI staining. Fluorescence microscopy was carried out using an AxioImager confocal microscope 
(Carl Zeiss, Jena, Germany). 
 
Orthotopic lung tumor animal models 
Animal experiments studies were approved by the institutional guidelines and by the European 
Community for the use of experimental animals (authorization to experiment 00393.02). H358-Luc 
or A549-Luc cells were harvested, washed and resuspended in PBS at 107 cells/50 µL (H358-Luc) 
or in PBS/0.5 mM EDTA at 5.106 cells/50 µL (A549-Luc). Six-week-old female nude mice (NMRI 
for H358 tumor model, BalB/c for A549 tumor model) (Janvier, Le Genest, Saint Isle, France) were 
anesthetized with an intraperitoneal injection of medetomidin (0.2 µg/g)/ketamine (0.1 mg/g), and 
the cells were inoculated in the lungs with a catheter after orotracheal intubation, as previously 
described (11, 18, 19). 
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Tumor growth was followed by in vivo bioluminescence imaging (IVIS Kinetic, Perkinelmer) 5 min 
after the intraperitoneal injection of 150 mg/kg of Luciferin (Promega, Charbonnières, France), as 
previously described (20).  
 
Nanoparticle in vivo administration 
Equal quantities of NPs were administered in healthy mice, H358-tumor bearing mice or A549-
tumor bearing mice after 5-6 weeks of tumor growth. Anesthetized mice (isoflurane/air 4% for 
induction and 1.5% thereafter) were injected intravenously via the tail vein with 200 µL of Dy-700 
labeled NP (8 mg/mL). Intrapulmonary administration of NP was performed using a nebulizing IA-
1C Microspayer (Penn-Centur, Inc, PA, USA) connected to a FMJ-250-high-pressure syringe 
(Penn-Centur, Inc) containing 50 µL of Dy-700 labeled NPs. After anesthesia with 
medetomidin/ketamine, the tip of the microsprayer was introduced into the trachea of the animals 
using a dedicated laryngoscope. 
 
Nanoparticle in vivo biodistribution  
Mice were anesthetized (isoflurane/air 4% for induction and 2% thereafter). 2D-fluorescent images 
and black and white pictures were acquired after intravenous or intrapulmonary administration 
using a back-thinned CCD camera at −80°C (ORCAII-BT-512 G, Hamamatsu, Massy, France) that 
was ﬁtted with a long-pass RG 700 ﬁlter, as previously described (21). At the end of the 
experiment, mice were sacrificed and some organs and blood were collected for ex vivo imaging. 
Semiquantitative data were obtained using the Wasabi® software (Hamamastsu, Massy, France) by 
drawing regions of interest (ROIs) on the different organs and were expressed as the number of 
Relative Light Units per pixel per unit of exposure time and relative to the fluorescence signal in the 
brain. 40 μL of blood were sampled from the tail vein before NP administration and at different 
times after, centrifuged (5 min at 8,000g) and 10 µL of plasma were used for fluorescence imaging. 
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Nanoparticle imaging in lung tumors and histology 
Bioluminescence and 2D-fluorescence signals were plotted along a line into the isolated tumor-
bearing lungs through healthy and tumor tissues according to the distance and quantified using the 
Zen® software. The ratio between the fluorescent signal in the tumor and the fluorescent signal in 
the adjacent healthy tissues was calculated. 
Confocal microscopy of the lung in frozen sections (30 µm) was carried out with a LSM710 LNO 
confocal microscope (Carl Zeiss, Jena, Germany) using a 60X oil immersion objective. The 702-nm 
laser intensity was set at 3% of its maximum intensity. Nuclei were labeled by DAPI. 
 
Statistical analysis 
All data are expressed as the mean ± SD. Statistical comparisons were made using a Mann-Whitney 
U-test. Two-sided p values ≤0.05 were considered statistically significant. All analyses were 
performed using the Statview software (Abacus concept, Berkeley, CA, USA). 
 
Results 
 
Preparation of nanoparticles 
A hydrophilic hyaluronan block was covalently linked by its reductive end to a hydrophobic PBLG 
(DP 20 and 60) using the 1,3 Huisgen cycloaddition, which combines mild experimental conditions, 
tolerance of functional groups and nearly quantitative yields (Figure 1A). An original and proper 
modulation of the copolymer composition and nanoprecipitation conditions (fast and slow 
processes) allowed the formation of two types of NPs, which had different sizes (Figure 1B). On the 
one hand, micellar NPs of 30 nm (Np30) were formulated using a fast nanoprecipitation process 
(with Hya-b-PBLG60). On the other hand, using Hya-b-PBLG20 and a slow process, polydispersed 
NP of 300 nm (Np300) were generated with a disc-like morphology, in co-existence with small 
micelles. To reduce the polydispersity and reach a pure NP morphology, 30% of homo-PBLG20 was 
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added in the initial copolymer solution, according to a recent report (17). The NPs were 
characterized by DLS, TEM, AFM and SANS (Figure 1C–F). 
 
Nanoparticles bind to NSCLC cells expressing different CD44 levels and are internalized 
The level of expression of CD44 was evaluated by flow cytometry in three different NSCLC cell 
lines (H322, H358 and A549 cells) (Figure 2A). H322 cells did not express CD44, whereas H358 
and A549 cells expressed low and high levels of CD44, respectively. Dose-dependent binding of 
Np30 and Np300 was observed in the three cell lines, with a higher intensity for A549 cells 
compared with H322 and H358 cells (Figure 2B). At high NP concentrations (80 and 160 µg/mL), 
Np30 binding was 2-3 times higher than Np300 binding in the three cell lines (Figure 2B and 
supplementary figure S1A). To further evaluate the specificity of NPs toward the hyaluronan cell 
surface receptors, competitive binding experiments were performed by pretreating the cells with 
saturating amounts of free hyaluronan (with MW ranging between 175-350 kDa) before NP 
incubation. Compared with the NP binding without hyaluronan pretreatment, the binding of Np30 
on H358 and A549 cells presented a 50-60% reduction in the mean fluorescence intensity (MFI) 
and a 50-70% reduction when Np300 was used (Figure 2C and supplementary Figure S1B). The 
inhibitory effect of hyaluronan pretreatment on NP binding increased with hyaluronan 
concentrations, especially with Np300. The presence of competitive free hyaluronan had no 
significant effect on Np30 or Np300 binding in H322 cells. The binding of these NPs on A549 and 
H358 cells were strongly inhibited by an excess of free hyaluronan, thus demonstrating that the 
hyaluronan cell surface receptors, particularly CD44 receptors, mediated the interaction. 
Finally, NP internalization was assessed using confocal microscopy in H358 and A549 cells (Figure 
2D). At 4°C, the internalization process was inhibited and both Np30 and Np300 were mostly found 
on the cell membrane, whereas at 37°C, punctate labeling was observed for Np30 and Np300, 
which is a hallmark of their intracytoplasmic trafficking after internalization. Cell labeling and 
internalization were stronger with Np30 than Np300. 
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Orthotopic lung tumors 
Orthotopic mouse models of human NSCLCs were established to evaluate the tumor targeting 
capability of the NPs. These models including the native tumor microenvironnement and 
angiogenesis are more relevant than the widely used subcutaneous tumors (11). Luciferase-modified 
human cell lines H358 (H358-Luc cells) or A549 (A549-Luc cells) were inoculated via the airways 
and noninvasive in vivo bioluminescence was used to monitor the quality of the implantation and to 
follow orthotopic growth (supplementary Figure S2). Both cell lines led to the development of 
localized lung tumors (11, 18, 19). Five weeks after implantation, tumors were well developed and 
had a strong bioluminescent signal, but the mice did not present any detectable symptoms such as 
body weight loss or breathing difficulties.  
 
Distribution of the nanoparticles after intravenous injection 
The blood pharmacokinetic of the NPs was measured in healthy mice by fluorescence imaging of 
plasma samples at different time postinjection (supplementary figure S3). The pharmacokinetic 
constants were calculated, and the theoretical distribution and elimination half-lives for Np30 (29 
and 673 min) were higher than for Np300 (10 and 44 min for distribution, and 196 min for 
elimination), which showed that Np30 had longer circulation times than Np300. 
Equal quantities of Dy-700-labeled Np30 or Np300 were injected intravenously in healthy or tumor 
bearing mice, and their biodistributions were assessed at multiple time points using 2D-FRI optical 
imaging. Liver uptake was fast and strong for both NPs in healthy and tumor-bearing mice, and the 
fluorescent signal remained stable over 24h (Figure 3A). At this time, the mice were euthanized, 
and the collected organs were subjected to ex vivo bioluminescence and fluorescence imaging 
(Figure 3B-D). For both NPs, the strongest fluorescence signals were measured in the liver and 
spleen, which highlighted their hepatic elimination. The Np30 and Np300 biodistribution patterns 
were similar in mice bearing tumors or not. The fluorescence of the lungs ex vivo was assessed to 
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compare the accumulation of NPs in healthy vs tumor-bearing lungs. The Np30 fluorescent signal 
was slightly higher in H358 tumor-bearing lungs and was 2 times higher in A549 tumor-bearing 
lungs than in healthy lungs (figure 4A). In contrast, the Np300 fluorescent signal in H358 tumor-
bearing lungs was not significantly different from the one in healthy lungs and was slightly 
decreased in A549 tumor-bearing lungs compared with healthy lungs.  
To evaluate whether the NPs accumulated preferentially in the tumor or healthy part of the lungs, 
the bioluminescence and fluorescence signals were overlaid, and their respective intensities plotted 
along a line (Figure 4B-C). We observed that the maximum of Np30 fluorescent signal co-localized 
with the tumor bioluminescent signal. The fluorescent signal was stronger in the tumor than in the 
surrounding healthy tissue, as evidenced by the fluorescence ratios of 1.61 ± 0.85 and 1.38 ± 0.29 in 
H358 and A549 tumor-bearing lungs respectively. By contrast, no tumor accumulation was detected 
for Np300. Indeed, the fluorescent signal was not significantly higher in H358 (1.04 ± 0.38) or 
A549 (1.35 ± 0.43) tumors than in the adjacent healthy tissues. Using confocal microscopy on lung 
sections, we observed weak Np30- and Np300-related fluorescent signals in healthy tissue and in 
H358 and A549 tumors (figure 4D), but these signals were too sparse to be quantified.  
Altogether, these results showed that after intravenous injection, both Np30 and Np300 were 
strongly retained by the liver. However, a very small proportion reached the lungs. Np30 
accumulated more strongly in the A549 and H358 tumor-bearing lungs, as compared with normal 
lungs (Figure 4A), and the fluorescence signal correlated well with the tumor bioluminescent signal. 
When Np300 was used, no particular accumulation in the invaded lung could be measured, and the 
NPs that were present in the lung were dispersed equally in the tumor and healthy areas.  
 
Distribution of the nanoparticles after intrapulmonary administration 
The NP biodistributions after the intrapulmonary administration of equal quantities of Dy-700-
labeled Np30 or Np300 were evaluated at multiple time points in healthy mice and H358- or A549-
tumor bearing mice. Representative images are shown in Figure 5A. Both Np30 and Np300 signals 
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were detected in the lungs immediately after administration in healthy and tumor-bearing mice, and 
they remained stable over 24h (Figure 5A). After quantification in the extracted organs at 24h 
(figure 5B), the fluorescence signal was 15 to 20 times higher in the lungs than in other organs, 
without significant differences between healthy and H358- or A549-tumor bearing mice (figure 5C-
D). No significant fluorescence signal was observed in the other organs, including liver or kidney, 
which confirmed a strong retention of the NPs in the airways. 
The levels of nebulized Np30 or Np300 in tumor-bearing lungs were not significantly different from 
those in healthy lungs (figure 6A), which indicates that the NPs did not accumulate in lung tumors 
after intrapulmonary administration. Bioluminescence and fluorescence signal overlays indicated 
that neither Np30 nor Np300 co-localized with the tumors (Figure 6B-C). The ratios between the 
fluorescent signals in tumors and in adjacent healthy tissues showed that the NP signals were higher 
in healthy tissue than in H358 or A549 tumors for both Np30 (0.59 ± 0.44 and 0.53 ± 0.11, 
respectively) and Np300 (0.50 ± 0.04 and 0.91 ± 0.50, respectively). The results were confirmed by 
confocal microscopy (figure 6D). Stronger fluorescence signals were observed in healthy tissue 
adjacent to the tumors than in lung tumors, thus illustrating that NPs did not reach lung tumor cells 
after intrapulmonary administration. In addition, the NPs’ access to the invaded areas of the lung 
was reduced by airway obstruction resulting from the presence of tumors. These animals were thus 
imaged with microCT and 3D-fluorescence tomography, in addition to bioluminescence. Examples 
of mice with well-established H358 lung tumors are shown in supplementary figure S4. From 
microCT acquisitions we reconstructed and extracted 3D images that represent the presence of air in 
the lungs. As can be seen on these images, the presence of tumors strongly reduced the volume of 
air in the lungs, and no NPs fluorescence signal was found in these “empty” regions of microCT in 
either Np30- or Np300-treated animals.  
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Discussion 
 
We generated hyaluronan-based NPs with two different sizes: nanospheres (Np30, 30 nm diameter) 
and disk-like NPs (Np300, 300 nm diameter). Regarding the large difference of size between the 
two types of NPs, it is expected that the differences in the biological behavior are mostly related to 
the size difference rather than the shape. We studied the influence of the size on the hyaluronan-
mediated CD44-dependent cellular binding in vitro and on their biodistribution profiles after 
intravenous or nebulization administration on mice bearing orthotopic lung tumors. 
 
Both Np30 and Np300 are made with low molecular weight hyaluronan (5 kDa). Hyaluronan is the 
natural ligand of the CD44 receptors and is overexpressed in many tumors (12). In addition to 
CD44, hyaluronan interacts with other cell surface receptors such as the receptor for hyaluronan-
mediated motility (RHAMM), the HARE receptor, Toll-Like receptors-2 and -4 (TLR-2 and TLR-
4) and LYVE-1 (22, 23). Our results showed the high expression of CD44 in A549 cells and its low 
expression in H358 cells. RHAMM is not expressed in A549 cells (24). The HARE receptor is 
mainly expressed in the sinusoidal endothelial cells of liver, spleen, and lymph nodes (22), LYVE-1 
in lymphatic tissue, and TLR-2/4 expressed in dendritic cells recognize hyaluronan during 
inflammatory events (25). These data indicated that CD44 should be the main hyaluronan receptor 
for mediating Np30 and Np300 binding on A549 and H358 tumor cells but that it is poorly 
implicated in H322 cells. In agreement, we observed that both NPs showed a dose-dependent 
binding on the cells, with A549 being more intensively stained than H358 and H322 cells. 
Competition assays with free hyaluronan showed a significant reduction of NPs binding 
corroborating the specificity to hyaluronan receptors. 
 
In order to compare the cellular uptake of NPs, we used Np30 and Np300 copolymer concentrations 
allowing equivalent signals of fluorescence and surface areas of binding. Np30 showed a higher 
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cellular binding and internalization than Np300, in agreement with studies that showed NPs with a 
20-25 nm radius achieved effective cellular uptake (8). The use of clathrin-mediated entry to 
internalize particles with sizes ranging from 10 to 300 nm has been reported (8). It has also been 
proposed that negatively charged NP, including hyaluronan-based NP, would be mostly internalized 
owing to caveolae-mediated endocytosis (8, 26). Internalization of nanodisks could also be slower 
than that of nanospheres, which could explain the difference between the Np30 and Np300 uptake 
profiles in NSCLC cells. Further experiments are needed to clarify if the cellular uptake differences 
for Np30 and Np300 are mainly due to size or shape. 
 
The behavior of NPs in vivo is strongly affected by their interaction with blood components and by 
biological factors, such as tumor presence, size, and location, angiogenesis, inflammation, and 
stroma thickness, composition, and rigidity. These factors will dramatically modify NPs surface 
properties in a highly dynamic and rapidly changing manner (7, 27). These aspects are difficult to 
investigate since it is very often impossible to recover the NPs in vivo to study their actual 
composition. 
Despite a longer circulation time for Np30, both Np30 and Np300 were rapidly taken up by the liver 
after intravenous injection. This observation is in accordance with the literature describing a rapid 
clearance by the kidneys for the small particles (<10 nm), whereas larger particles are more 
efficiently captured by the RES and sequestered by the liver because of opsonization and protein 
association on the NP surface (7, 28-30). In addition, Np30 and Np300 are negatively charged, 
which is also a key factor that drives NP behavior, promoting recognition by the RES and uptake by 
the liver (7, 31).  
Semiquantitative measure of fluorescence signal (32) showed that Np30 was significantly higher in 
A549 tumor-bearing lungs than in healthy lungs. This could be in part explained by the enhanced 
permeability and retention (EPR) effect: the tumor vasculature is irregular, leaky, and dilated, and 
the vascular endothelial cells are poorly aligned with large fenestrations, resulting in the increased 
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leakage of nanocarriers from the circulatory system into the tumor tissue (33). Accordingly, the 
longer circulation time measured for Np30, compared with Np300, could explain the higher 
accumulation of Np30 in tumor-bearing lungs. However, Np30 accumulation was significantly 
higher in the CD44-overexpressing A549 tumor cells than in H358 low-expressing cells or in 
healthy tissue, which suggests that CD44 receptor active targeting could play a role in Np30 
retention in lung tumors, although this has yet to be formally established.  
 
The intrapulmonary delivery of antitumoral agents might enhance their amount at the targeted lung 
cancer site, thereby improving NP accumulation in tumors and the antitumoral effect (9, 11). The 
nebulized NPs presented a similar and very strong accumulation in healthy, H358 or A549 lungs, 
and the fluorescent signal remained stable for at least 72h (data not shown). Moreover, no 
fluorescence signal was observed in the other organs, in contrast to ultra-small NP (<6 nm), which 
showed a passage from the airways to the blood after nebulization and a renal elimination (11). The 
larger size of Np30 and Np300 could explain their long retention in the lungs without diffusion into 
the blood stream. As a consequence, this would also prevent such NPs from “returning” to the 
tumors via the blood circulation and the EPR effect. 
The semiquantitative measure of fluorescence signals (32) of both NPs were not different between 
tumor-bearing and healthy lungs and confocal microscopy demonstrated that NPs did not reach 
tumor tissue. The bronchial obstruction due to the presence of tumor nodules might prevent the 
NP spray from penetrating the tumor, and thus might accumulate in healthy tissue. 
 
In summary, we demonstrated that the size of hyaluronan-based NPs plays a critical role in cellular 
uptake, in correlation with the CD44 level. In the NSCLC cells, NP of 30 nm were bound and 
internalized more efficiently than were the 300 nm NP. In vivo studies showed that direct 
administration of these NPs into the airways failed to increase their uptake by the tumors. However, 
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their intravenous injection showed a preferential and possibly active targeting of CD44-positive 
tumors for 30 nm NPs that could not be documented for the 300 nm NPs.  
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Figure legends 
Figure 1: Synthesis and self-assembly of the hyaluronan-b-PBLG copolymer. 
A: Chemical pathway toward hyaluronan-b-PBLG copolymer and its labeling with the fluorescent 
dye Dy-700. B: Elaboration of bock copolymer NP through a fast or slow nanoprecipitation 
protocol. C: Characterization of block copolymer NP by static and dynamic light scattering. RH: 
hydrodynamic radius, PDI: polydispersity index, Mw: weight-average molecular weight, Nagg: 
aggregation number (=number of copolymer chains in a NP); Rg,z: z-average root-mean-square 
radius of gyration. D: intensity-weighted size distribution of NP obtained by DLS analysis at a 
detection angle of 90°. E, F: AFM pictures of Np30 (E, 500 x 500 nm) and Np300 (F, 3 x 3 µm). 
 
Figure 2: In vitro uptake of nanoparticles by NSCLC cells. 
A: Flow cytometry histograms shows cells stained with FITC-CD44 antibodies (blue curve), FITC-
IgG2b (red curve), or without antibodies (black curve). B: Concentration-dependent binding of Dy-
700-labeled Np30 (left) and Np300 (right) after 30 min at 37°C in H322, H358 and A549 cells. The 
results are expressed as the mean fluorescence intensity (MFI) ±SD normalized against untreated 
cells (n=3). C: Np30 (left) and Np300 (right) (8 µg/mL) binding to H322, H358, and A549 cells 
with or without 5 or 10 mg/mL hyaluronan (HYA) pretreatment. The results are expressed as the 
percentage of the MFI±SD normalized against cells without HYA pretreatment (100%) (n=3). 
*p≤0.05, compared with NP treatment without HYA pretreatment. D: Confocal microscopy images 
display cellular binding and internalization of 160 µg/mL NPs in H358 and A549 cells after 30 min 
at 4°C and 37°C. Blue channel: DAPI-stained nuclei; red channel: Dy-700-labeled NPs; 
magnification: 60X. 
 
Figure 3: Biodistribution of fluorescent nanoparticles after intravenous administration in 
orthotopic lung tumors. 
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In vivo biodistribution of Dy-700-labeled NPs in healthy, H358-Luc, or A549-Luc lung tumor-
bearing mice were studied. A: Fluorescence images (500 ms integration time) were recorded at 
different times after injection (min-max: frontal 1745-30629; back 1745-7498). An example of the 
biodistribution in healthy mice treated with Np30 and Np300 is presented (for each NP: upper line, 
dorsal view of the mouse; lower line, ventral view of the mouse). B: Fluorescence images were 
performed on isolated organs 24h after injection. An example of organs extracted from a healthy 
mouse treated with Np30 is presented. C-D: ROI are defined on the extracted organs to semi-
quantify the amount of photons detected per pixel after a 200 ms exposure. The results in each 
organ are expressed as the mean ±SD in healthy mice and H358-tumor bearing mice (n≥5) (C) or 
A549-tumor bearing mice (n≥4) (D).  
 
Figure 4: Colocalization of bioluminescence and fluorescence in orthotopic lung tumors after 
intravenous administration of nanoparticles. 
A: ROI were defined in the extracted lungs to semi-quantify the amount of photons detected per 
pixel after 200 ms exposure after intravenous injection of NPs. The results are expressed as the 
mean ±SD and as the rate of signal in healthy mice. H358-tumor bearing mice n≥5, A549-tumor 
bearing mice n≥4. *p≤0.05, compared to healthy mice. B-C: Bioluminescence and fluorescence 
imaging was performed on isolated lungs, and showed a colocalization between the H358-Luc (B) 
or A549-Luc (C) lung tumors (bioluminescence, in red) and the fluorescent NP (fluorescence, in 
green). Bioluminescent and fluorescent signals are plotted according to the distance in lungs 
(arrows). D: Lung tumors were extracted and cryosectioned before confocal microscopy 
observation. In blue: DAPI-stained nuclei; in red: Dy-700 signal; in white and black: superimposed 
visible light images. Np30 or Np300 signals in adjacent healthy tissue (a and d), H358 tumors (b 
and e) or A549 tumors (c and f). Magnification: 60X.  
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Figure 5: Biodistribution of fluorescent nanoparticles after nebulization in orthotopic lung 
tumor. 
In vivo biodistribution of Dy-700-labeled NPs in healthy, H358-Luc, or A549-Luc lung tumor-
bearing mice were studied. A: Fluorescence images (500 ms integration time) were recorded at 
different times after nebulization (min-max: 1774-6508). An example of biodistribution in A549 
tumor-bearing mice treated with Np30 and Np300 is presented (for each NP: upper line, dorsal view 
of the mouse; lower line, ventral view of the mouse). B: Fluorescence images were obtained of 
isolated organs 24h after nebulization. An example of organs extracted from an A549 tumor-bearing 
mouse treated with Np30 is presented. C-D: ROI were then defined on the extracted organs to semi-
quantify the amount of photons detected per pixel after a 200 ms exposure. The results in each 
organ are expressed as the mean ±SD in healthy mice and H358-tumor bearing mice (n≥3) (C) or 
A549-tumor bearing mice (n>3) (D).  
 
Figure 6: Colocalization of bioluminescence and fluorescence in orthotopic lung tumors after 
nebulization of nanoparticles. 
A: ROI were defined in the extracted lungs to semi-quantify the amount of photons detected per 
pixel after 200 ms exposure after intrapulmonary administration of NPs. The results are expressed 
as the mean ±SD and as rate of signal in healthy mice (n≥3 mice per group). B-C: Bioluminescence 
in H358-Luc (B) or A549-Luc (C) lung tumors (bioluminescence, in red) and fluorescence of Np30 
or Np300 (fluorescence, in green) imaging were performed on isolated lungs. Bioluminescent and 
fluorescent signals are plotted according to the distance in lungs (arrows). D: Lungs tumors were 
extracted and cryosectioned before confocal microscopy observation. In blue: DAPI-stained nuclei; 
in red: Dy-700 signal; in white and black: superimposed visible light images. Np30 or Np300 
signals in adjacent healthy tissue (a and d), H358 tumors (b and e) or A549 tumors (c and f). 
Magnification: 60X.  
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Supplementary Fig S1 
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Supplementary"Figure"S1:!
A:! Representa+ve! ﬂow! cytometry! histograms! showing! H322,! H358! and! A549! cells! stained! with!
Dye700Dlabeled! nanopar+cles! at! 160! µg/mL! (Np30,! red! curve;! Np300,! blue! curve;! no! nanopar+cle,!
black!curve)!aQer!30!min!at!37°C.!
B:" Representa+ve! ﬂow! cytometry! histograms! displaying! the! rela+ve! ﬂuorescence! intensity! of!
unstained!control!H322,!H358!or!A549!cells!(black!curve),!or!cells!treated!with!8!µg/mL!Np30!(upper!
panel)! or! Np300! (lower! panel)! with! (red! curve)! or! without! 5! mg/mL! hyaluronan! 175D300! kDa!
pretreatment!(blue!curve).!
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Supplementary"Figure"S2:"H358"and"A549"orthotopic"lung"cancer"mouse"models.!
A:! Lung! tumors! development! of! intrapulmonary! inocula5on! of! luciferase6modiﬁed! human! lung! cancer! H358!
(H3586Luc)! or! A549! (A5496Luc)! cells! was! followed! using! bioluminescence! in# vivo! at! the! indicated! 5mes.!BAC:!
Detec5on!of!lung!tumor!nodules!on!lung!sec5ons!aFer!hematoxylin!and!eosin!staining!in!H358!(B)!and!A549!(C)!
orthotopic!tumors.!Images!are!at!4X!(leF)!and!20X!magniﬁca5on!(right).!!
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Blood samples 
Supplementary,Figure,S3:,Nanopar4cles,distribu4on,and,elimina4on,blood,imaging.!
Healthy!mice!were! injected! intravenously!with!Dye7008labeled!Np30! (n=5)!or!Np300! (n=4).! The!ﬂuorescence!
intensity! measurements! of! blood! samples! were! performed! over! Fme! for! each! nanoparFcle.! The! results! of!
theses!measurements!are!expressed!as!the!mean!±!SD!and!the!exponenFal!decay!parameters!were!ﬁKed.!
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Supplementary,Figure,S4:"In"vivo,H3585Luc,orthotopic,lung,tumor,imaging.!
Dy700! labeled! Np30! or! Np300! were! administered! intrapulmonary! in! H358! lung! tumor;bearing! mice.!
Bioluminescence,!microCT,!and!3D;ﬂuorescence!tomography!imaging!were!performed!24h!aGer!nebulizaIon!of!
nanoparIcles.! Bioluminescent! signal! showed! H358;Luc! tumor! cells! in# vivo.! 3D;ﬂuorescent! signal! showed!
nanoparIcles!locaIon!in!thoracic!region.!MicroCT!analysis!showing!the!air!in!the!lungs,!solid!tumor!locaIon!was!
observed!through!absence!of!signal!on!image!of!the!lungs.!The!3D!ﬂuorescent!signal!was!merged!with!the!mice’s!
lungs!in!order!to!replace!the!ﬂuorescent!signal!in!an!anatomical!context.!For!each!mouse,!a!dorsal!view!(upper!
line)!and!a!ventral!view!(lower!line)!were!shown.!White!doSed!line:!tumor!site.!
